You are currently viewing Cannabis Science: Providing Innovative Therapeutics for Unmet Medical Needs

Cannabis Science: Providing Innovative Therapeutics for Unmet Medical Needs

Cannabis Science, Inc. is a public U.S. company specializing in the research and development of cannabinoid-based medicines targeting critical ailments, such as various cancers, HIV/AIDS, Post Traumatic Stress Syndrome (PTSD), neurological disorders, chronic pain, Chronic Obstructive Pulmonary Disease (COPD), and arthritis.
A Vertically Integrated Company
Cannabis Science’s objective is to create a vertically integrated organization, through investing in the organic growth and development of the Company’s operational capabilities, as well as through strategic acquisitions. Cannabis Science aims to control the development of its medicines from farm-to-bedside, and firmly establish the Company as a leader and recognized innovator in the market for cannabinoid-based medicines.
A Leader in Research and Product Development
Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments. To help accomplish this, Cannabis Science recently launched the Cannabis Science Global Consortium as a framework and platform to cooperate and collaborate with stakeholders worldwide. The Cannabis Science Global Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside. The Global Consortium also enables the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.
Cannabis Science is aggressively expanding the Company’s network of research centers. Negotiations are ongoing with several academic institutions in the United States and internationally to establish new, collaborative research agreements. These contracts will focus on several indications, and are expected to expand the research funded and directed by the Company. In addition, Cannabis Science will develop multi-center, clinical trial networks with cannabinoid drug development.
“Cannabis Science currently has several research programs underway that have produced promising, initial results that are critical in the Company’s early phase cancer drug development plan,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, Chief Executive Officer (CEO), and Co-founder. Based on the Company’s progress to date, Cannabis Science expects to conclude pre-clinical work on a few cannabinoids over the next several months, and begin clinical trials in 2018.
There are three primary elements in Cannabis Science’s drug development program:

  • Defining the effectiveness and specificity of cannabinoids being tested;
  • Identifying and testing drug delivery mechanisms; and
  • Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials.

The Company’s initial results point to the importance of drug delivery systems and the impact of co-interventions.
The initial results of Cannabis Science’s research were published in September 2017. The Company’s peer-reviewed article in Frontiers in Oncology, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, has been viewed more than 11,000 times, and has more views than 96% of all Frontiers’ articles.
“This strong – and increasing – level of interest by our colleagues validates the importance of our research,” stated Mr. Dabney. “We believe that our Company, along with our collaborators, are helping to better understand the science as it pertains to the use of cannabinoids in cancer therapeutics and novel ways of drug delivery and targeting. In so doing, we expect to develop medicines that can positively impact so many patients in the U.S. and worldwide.”
Cannabis Science’s second article, “Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids”, was published in Frontiers in Oncology on April 24, 2017.
Engaging Patients and Stakeholders
Cannabis Science recognizes that the success of its business is fully-dependent on the Company meeting the needs of its customers through the development of high-quality and cost-effective cannabinoid-based medicines. In order to engage with the Company’s customers, as well as all stakeholders, Cannabis Science has launched a new online platform, iCannabinoid, and has plans to open a number of pharmacies and medical centers in California, initially, and ultimately throughout the United States. This approach will enable the Company to engage and interact with its customers and stakeholders, in a variety of manners, to ensure Cannabis Science understands the needs of its customers and provides platforms for the exchange of ideas related to the medical marijuana industry.
Cannabis Science’s Online Platform – iCannabinoid
Cannabis Science has completed a successful beta launch of iCannabinoid, the Company’s state-of-the-art, social media and educational website. iCannabinoid is designed to serve as an information center, resource hub, and support group for all seeking alternative cannabinoid treatments including patients, advocates, doctors, researchers, parents, lawyers, growers, journalists, government, private-sector leaders, community organizers, and others.
iCannabinoid Members can educate and inspire each other 24/7 with the ability to track and share their personal experiences of cannabinoid treatments through action groups, chats, blogs, photos, and videos. iCannabinoid provides opportunities for medical practitioners to directly interact with and help patients. Personal My Health Modules are also available for Members to track and set health goals. iCannabinoid involves the community through the Ambassador Program which allows passionate, qualified volunteers to help spread the word and assist individuals in their areas of expertise. iCannabinoid also provides overall support information such as the science of cannabinoids, critical ailment definitions, supplementary treatments available, marijuana laws and regulations, and relevant research studies. This platform empowers patients to educate themselves through sharing information about the potential benefits of using cannabinoids as a complementary therapy. For more information on iCannabinoid, please visit
Cannabis Science’s Medical Centers
As an important component of Cannabis Science’s strategy to engage patients and stakeholders directly, the Company has plans to open a number of medical centers initially in California. Cannabis Science successfully completed the soft opening of its first CBIS Medical Center on 4/20. The CBIS Medical Center is located at 14006 Ventura Boulevard, Sherman Oaks, California 91423, and is the first of several locations that Cannabis Science plans to open throughout California in the coming months and years.
The opening of the first CBIS Medical Center location is an important part of Cannabis Science’s growth strategy. CBIS Medical Center locations will showcase Cannabis Science brands of high-quality cannabinoid and cannabis-based products and accessories for patients, doctors, and the consuming public. These products will range from pills, creams, extracts, sprays, tinctures, edibles, balms, patches, oils, raw products, and merchandise. The locations will also showcase other brands as well, in order to provide the widest possible selection of products for the Company’s patient community.
The Cannabis Science Medical Centers, will include full laboratory facilities, patient intake, and doctor and nurse clinics. Cannabis Science will explore opportunities to provide U.S. federal government-approved Emergency Medical Services, leveraging the Company’s eligibility to receive federal government contracts and grants. Cannabis Science is one of the few companies in its industry to be registered in the federal government’s System for Award Management (SAM), and to have received a Commercial and Government Entity (CAGE) Code from the Department of Defense’s (DoD) Defense Logistics Agency (DLA) CAGE Program Office. Cannabis Science is registered in SAM to provide services primarily in three areas – Research and Development in Biotechnology, Medical Laboratories, and Emergency and Other Relief Services.
“Cannabis Science is currently exploring a number of Federal government contracts and grant opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others,” stated Mr. Dabney. “I believe we have a significant role to play, as a private-sector stakeholder, as well as a company that can support federally-funded contracts and grant opportunities as an experienced contractor.”
Corporate Social Responsibility
Cannabis Science believes in Corporate Social Responsibility (CSR) and that companies should have an obligation to positively impact the communities in which they operate – this includes investment in infrastructure, job creation, and skills training. In the area of CSR, the Company leads by example. Cannabis Science has launched its Economic Development Initiative (EDI) to provide general structure for how the Company operates in the communities where it has established business activities. Through its EDI, Cannabis Science develops and implements specific initiatives to meet the needs of each community, as identified through consultation with members of the community.
For example, in partnership with Free Spirit Organics Native American Corporation (FSO NAC), Cannabis Science has developed an economic development plan in San Joaquin County, California, where the aim is to provide education and skills training for community residents in science, agriculture, and pharmaceutics that will help create jobs and improve overall economic conditions in Stockton County. Part of this joint development plan includes the planting and harvesting of 250 acres of industrial hemp, and establishing the American States University (ASU) to provide students with a unique hybrid of online, in class, and field education. Through its educational partners – ASU, American Heritage University School of Law (AHUSOL), and Raymond C. Dabney University (RCDU) – Cannabis Science creates opportunities for students for experiential learning of cannabinoids, focusing on the research and development of all-natural pharmaceutical drugs for target ailments.
American States University
American States University offers thirty-seven state-approved post secondary educational programs in the Departments of Agriculture, Arts, Business, Certified Professional, and Technology in a unique hybrid structure of online, in class, and in field education. Its primary purpose is to provide professional training in agricultural hemp research and development for pharmaceutical drugs targeting critical ailments such as Cancer, Epilepsy, Chronic Pain, Parkinson’s Disease, Arthritis, PTSD, HIV/AIDs and other industries such as Alternate Biofuels, Construction, Clothing and Automobile Materials, business administration, and other numerous certifications. The University aims to provide affordable quality education to its students so as to achieve their career goals and excel in their chosen professions. A sample curriculum for the Alternative Medicine Hemp 101 Program includes; Regulatory Compliance, Company Creation, Company Structure, Department Management, Team, Management, Planting and Harvest, Formulation Creation, Manufacturing, Wholesale, Distribution, Observational Studies, Retail, Sales, and Marketing.
Cannabis Science is also filming a three-part documentary on the agricultural farm where the industrial hemp is grown. The docu-series will shed a light on the science, technology, and research that the company utilizes to develop novel cannabinoid-based medications to offer a better understanding of what Cannabis Science means, what the Company does, and the driving forces behind the Company. Cannabis Science hopes to raise public awareness about the medical benefits of medical marijuana and ultimately shape current governmental legislation to better reflect the needs and demands of modern society. Additionally, the Company is producing 30-60 second advertisements to be broadcasted on television.
African Initiative
As part of the Company’s global CSR initiative, Cannabis Science has created an African Initiative with the goal of helping to accelerate economic development throughout Africa, with a focus on educational and job-creation initiatives. In implementing its work in Africa, Cannabis Science collaborates closely with the Constituency for Africa (CFA). For over 26 years, CFA has established itself as one of the leading, non-partisan organizations focused on educating and mobilizing the American public and the African Diaspora in the U.S. on U.S.-Africa policy.  As a result, CFA has helped to increase the level of cooperation and coordination among a broad-based coalition of individuals and organizations committed to the progress, development, and empowerment of Africa and African people worldwide. Mr. Dabney is a Member of CFA’s Board of Directors, and a Co-chair of CFA’s African Healthcare Infrastructure Committee. Key objectives of Cannabis Science’s African Initiative include:
Agriculture & Drug Development: Cannabis Science plans to establish viable operations throughout Africa inclusive of growing operations, research and drug development, multi-center clinical trials, manufacturing and sales. Cannabis Science intends to supply the African market with cannabinoid-based medicines to treat a number of indications, as well as to export medicines from Africa to other markets worldwide.
Healthcare Infrastructure: The Company will help establish hospitals, health centers, and related educational facilities, to also include drug development.
Food Safety: Cannabis Science operates from the farm to the table. In that light, food security begins with sound agricultural practices that produce sufficient food for consumption and that are designed to reduce poverty. Water management and safety, food preservation and safety are additional core components of sound agriculture and food policy. Environmental factors are important risk factors for infectious disease epidemics. Cannabis Science also believes that rigorous waste management and sanitation are vital epidemic control mechanisms.
Political Environment: The Company recognizes the need to impact policy, regulatory, and jurisdictional contexts that outline public healthcare; as well as agricultural, educational and training contexts that in turn define the health and economic well-being of all communities.
Education and Job Creation: At the heart of job creation is education and training. Sustainable models of education and training are associated with important areas of development, including industrial sectors such as drug development/treatments, agriculture/food safety, communications, investments, and engaging political environments.
Technology and Communication: Satellite, Internet, mechanical device development, and cellphone infrastructure are all important components of healthcare, educational, and economic development. In addition, dynamic media exposure defines how communities perceive themselves and respond to their problems.
Architect Behind Cannabis Science
Raymond C. Dabney is the President, CEO, and Co-Founder of Cannabis Science. With more than 25 years of experience in corporate finance, sales, and management under his belt, Mr. Dabney is equipped with a niche market experience that is crucial in realizing the company’s full potential. He has formed extensive international relationships with several leaders in science and public service that contributes to company growth and prosperity. His insight to public and private venture capital, early stage equity, debt financing and regulatory compliance is crucial for growing companies in the U.S., Canada, Europe and South Africa. Mr. Dabney has received the 2018 Harvard GHC Industry Leader award in recognition of his impactful efforts, bold vision, and ground-breaking collaborations with African country institutions. As a member of the Constituency for Africa’s (CFA) Board of Directors, Mr. Raymond is passionate about improving the healthcare infrastructure throughout Africa. Having visited South Africa and Namibia in 2016 for the first time, he sees the opportunity for Cannabis Science to engage with key African stakeholders in government, academia, and civil society to accelerate the company’s African drug-development initiative, EDI, and build on research collaborations.
Source :-The 50 Best Companies to Watch 2018